keyword
MENU ▼
Read by QxMD icon Read
search

Ptcl

keyword
https://www.readbyqxmd.com/read/29442288/updates-of-peripheral-t-cell-lymphomas-based-on-the-2017-who-classification
#1
REVIEW
Parwiz J Siaghani, Joo Y Song
PURPOSE OF REVIEW: This review will describe and update the readers on the recent changes of the 2017 WHO classification in regard to peripheral T cell lymphomas. RECENT FINDINGS: Significant advances in molecular studies have resulted in revisions of the classification as well as introduction of provisional entities (such as breast implant-associated ALCL, nodal PTCL with TFH phenotype). Major advances in molecular and gene expression profiling have expanded our knowledge of T cell lymphomas, including updates in the diagnostic criteria and sub-classification which will facilitate in improving patient care and research...
February 14, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29434288/stem-cell-transplantation-for-t-cell-lymphomas-in-taiwan
#2
Ya-Ting Hsu, Hui-Jen Tsai, Jeffrey S Chang, Sin-Syue Li, Jih-Luh Tang, Su-Peng Yeh, Wen-Li Hwang, Jin-Hwang Liu, Tran-Der Tan, Po-Nan Wang, Hui-Hua Hsiao, Tsai-Yun Chen
T-cell lymphomas are generally aggressive malignancies with poor prognosis. There are no standard treatment guidelines for T-cell lymphomas, and the timing of stem cell transplantation (SCT) is not well known. In this study, we investigated the outcomes of Taiwanese patients with T-cell lymphomas after SCT. We retrospectively analyzed 131 patients with T-cell lymphomas receiving SCT (autologous: 90, allogeneic: 41) from 2009 to 2014. More autologous SCT recipients were ALCL or in complete remission, and more allogeneic recipients had advanced disease...
February 12, 2018: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29415977/composite-lymphoma-as-co-occurrence-of-advanced-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-carrying-trisomy-12-and-t-14-18-and-peripheral-t-cell-lymphoma
#3
Yumi Aoyama, Taiichi Kodaka, Yuriko Zushi, Yuta Goto, Hiroko Tsunemine, Tomoo Itoh, Takayuki Takahashi
Composite lymphoma is defined as the co-occurrence of two types of lymphoma, comprising 1-4% of lymphomas, and the association of B-cell-type chronic lymphocytic leukemia (B-CLL)/small lymphocytic lymphoma and peripheral T-cell lymphoma (PTCL) is rare. Here, we report a case (77-year-old woman) of advanced B-CLL complicated by newly appearing PTCL. Two years after the onset of B-CLL, CLL cells acquired CD38 antigen expression and the disease entity became CLL/prolymphocytic leukemia. Trisomy 12 and t(14;18) karyotypes were observed...
February 8, 2018: Journal of Clinical and Experimental Hematopathology: JCEH
https://www.readbyqxmd.com/read/29414251/pathogenesis-of-peripheral-t-cell-lymphoma
#4
Marco Pizzi, Elizabeth Margolskee, Giorgio Inghirami
Peripheral T cell lymphomas (PTCLs) are highly heterogeneous tumors, displaying distinct clinical and biological features. The pathogenesis and normal counterpart of such entities have been elusive for decades. Recent studies have, however, disclosed key mechanisms of peripheral T cell transformation, including (a) the deregulation of signaling pathways controlling T cell development, differentiation, and maturation; (b) the remodeling of the peritumor microenvironment; and (c) the virus-mediated rewiring of T cell biology...
January 24, 2018: Annual Review of Pathology
https://www.readbyqxmd.com/read/29397528/the-future-of-combination-therapies-for-peripheral-t-cell-lymphoma-ptcl
#5
REVIEW
Helen Ma, Ardy Davarifar, Jennifer E Amengual
PURPOSE OF REVIEW: Peripheral T cell lymphoma is a rare heterogeneous group of diseases which are characterized by poor outcomes to treatment and short overall survival. In the past decade, several new therapies targeting T cell biology have been approved in the relapsed setting. These new therapies, such as pralatrexate, romidepsin, belinostat, and brentuximab vedotin, have begun to make their way into practice. Despite these advances, outcomes have not changed dramatically. In recent years, efforts have been made to incorporate these new therapies into combination strategies to treat this challenging disease entity...
February 3, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29380399/immunohistochemical-assessment-of-the-diagnostic-utility-of-pd-l1-a-preliminary-analysis-of-anti-pd-l1-antibody-sp142-for-lymphoproliferative-diseases-with-tumour-and-nonmalignant-hodgkin-reed-sternberg-hrs-like-cells
#6
Ayako Sakakibara, Kei Kohno, Ahmed E Eladl, Teerada Klaisuwan, Eri Ishikawa, Yuka Suzuki, Satoko Shimada, Masato Nakaguro, Yoshie Shimoyama, Taishi Takahara, Seiichi Kato, Naoko Asano, Shigeo Nakamura, Akira Satou
AIMS: The programmed death 1 (PD1)/PD1 ligand (PD-L1) axis plays an important role in tumour cells escape from immune control. PD-L1 immunohistochemistry is a useful predictor of immunotherapy response, but is still not widely used in the diagnostic setting. Here we describe results using PD-L1 immunohistochemistry during routine diagnostics in lymphoma. METHODS AND RESULTS: Ninety-one lymphoproliferative disease cases sharing tumour and nonmalignant Hodgkin/Reed-Sternberg (HRS)-like cells with and without Epstein-Barr virus (EBV) association were investigated by immunohistochemistry for PD-L1 (clone SP142)...
January 30, 2018: Histopathology
https://www.readbyqxmd.com/read/29374824/central-nervous-system-involvement-in-peripheral-t-cell-lymphoma
#7
REVIEW
Dai Chihara, Yasuhiro Oki
PURPOSE OF REVIEW: Central nervous system (CNS) involvement in peripheral T cell lymphoma (PTCL) is a difficult condition to treat, both as a primary and a secondary disease. RECENT FINDINGS: Primary CNS lymphoma (PCNSL) in PTCL is very rare, making up only 2% of all PCNSLs. The incidence of CNS relapse is generally 2-6% in all cases of PTCL, but the risk may vary by histologic subtype, and extranodal involvement > 1 has been consistently found to be a risk factor for CNS relapse...
January 27, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/29368793/different-aberrant-expression-pattern-of-immune-checkpoint-receptors-in-patients-with-ptcl-and-nk-t-cl
#8
Ziwei Liao, Xuewen Lv, Sichu Liu, Zifan He, Shaohua Chen, Liang Wang, Wenyu Li, Yangqiu Li
AIM: To better understand the T-cell immunodeficiency status in patients with peripheral T-cell lymphomas (PTCLs) and NK/T-cell lymphomas (NK/T-CLs), the T-cell inhibitory receptors expression pattern was investigated. METHODS: The expression levels of programmed death 1 (PD-1), cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), B/T lymphocyte attenuator (BTLA), lymphocyte-activation gene 3 (LAG-3), T-cell immunoglobulin-3 (TIM-3), T-cell immunoglobulin and ITIM domain (TIGIT) genes were detected in peripheral blood mononuclear cells (PBMCs) from patients and healthy volunteers by quantitative real-time-PCR, the correlation between different gene expression levels was analyzed...
January 25, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29361706/a-multicentric-t-cell-lymphoma-with-a-plasmacytoid-morphology-in-a-dog
#9
Alissa Bally, Karelma Frontera Acevedo, Indira Pargass, Lana Gyan, Stacy Rajh, Rod Suepaul
An 8-year-old male (neutered) Labrador with a history of erythematous skin lesions and exercise intolerance for a prolonged period was suddenly found dead. Necropsy findings revealed an infiltrative, focally extensive mass which occupied 25% of the cardiac interventricular septum. Severe endocardiosis was also found on the bicuspid and tricuspid valves. The submandibular lymph nodes and kidneys were bilaterally enlarged, and the pre-hepatic lymph node and spleen were also enlarged. Multiple dermal pustules were present around the mouth and on the ear, and small ulcers were present on the tongue...
January 20, 2018: Veterinary Sciences
https://www.readbyqxmd.com/read/29348865/targeting-t-cell-malignancies-using-anti-cd4-car-nk-92-cells
#10
Kevin G Pinz, Elizabeth Yakaboski, Alexander Jares, Hua Liu, Amelia E Firor, Kevin H Chen, Masayuki Wada, Huda Salman, William Tse, Nabil Hagag, Fengshuo Lan, Elaine Lai-Han Leung, Xun Jiang, Yupo Ma
Peripheral T-cell lymphomas (PTCLs) are a group of very aggressive non-Hodgkin's lymphomas (NHLs) with poor prognoses and account for a majority of T-cell malignancies. Overall, the standard of care for patients with T-cell malignancies is poorly established, and there is an urgent clinical need for a new approach. As demonstrated in B-cell malignancies, chimeric antigen receptor (CAR) immunotherapy provides great hope as a curative treatment regimen. Because PTCLs develop from mature T-cells, these NHLs are commonly CD4+, and CD4 is highly and uniformly expressed...
December 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/29341369/structural-factors-affecting-binding-of-platinum-anticancer-agents-with-phospholipids-influence-of-charge-and-phosphate-clamp-formation
#11
Anil Kumar Gorle, Junyong Zhang, Qin Liu, Susan J Berners-Price, Nicholas P Farrell
We report a detailed NMR and DFT study of the interaction of polynuclear platinum anticancer agents (PPCs) with negatively charged phospholipids as a mechanism for their cellular uptake. The reactions of fully 15N-labelled [{trans-PtCl(NH3)2}2(-trans-Pt(NH3)2{NH2(CH2)6NH2}2)]4+ (15N-1, 1,0,1/t,t,t) and the dinuclear [{trans-PtCl(NH3)2}2{-H2N(CH2)6NH2}]2+ (15N-2, 1,1/t,t) with the sodium salt of 1,2-dihexanoyl-sn-glycero-3-phosphate (DHPA) were studied at 298 K, pH ~5.4, by [1H,15N] HSQC 2D NMR spectroscopy...
January 17, 2018: Chemistry: a European Journal
https://www.readbyqxmd.com/read/29333403/treatment-outcomes-of-dose-attenuated-chop-chemotherapy-in-elderly-patients-with-peripheral-t-cell-lymphoma
#12
Eun-Ji Choi, Jung Yong Hong, Dok Hyun Yoon, Jihoon Kang, Chan-Sik Park, Jooryung Huh, Eun Jin Chae, Yoonse Lee, Jin-Sook Ryu, Cheolwon Suh
Background: While cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is the most commonly used chemotherapeutic regimen for patients with peripheral T-cell lymphomas (PTCLs), elderly patients are more vulnerable to associated toxicities. We evaluated the efficacy and safety of dose-attenuated CHOP in elderly patients with PTCL. Methods: Patients with PTCL aged >70 years or 65-70-years with comorbidities were treated with dose-attenuated CHOP (cyclophosphamide: 562...
December 2017: Blood Research
https://www.readbyqxmd.com/read/29302559/peripheral-t-cell-lymphoma-not-otherwise-specified
#13
Kunal Kishor Jha, Suresh K Gupta, Harpreet Saluja, Nuwadatta Subedi
The peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS) belongs to a heterogeneous class of aggressive neoplasms. Although several morphologic subtypes of this tumor have been described, no particular genetic, immunological, or distinct clinical features define this disease. Patients can experience night sweats, fever, lymphadenopathy, weight loss, splenomegaly, and/or skin changes. Common laboratory tests reveal that patients have anemia, thrombocytosis, lymphocytosis, eosinophilia, hypergammaglobulinemia, or increased lactate dehydrogenase...
April 2017: Journal of Family Medicine and Primary Care
https://www.readbyqxmd.com/read/29296861/redefining-the-role-of-etoposide-in-first-line-treatment-of-peripheral-t-cell-lymphoma
#14
Young Ae Kim, Ja Min Byun, Keeho Park, Gi Hwan Bae, Dukhyoung Lee, Dong Sook Kim, Sung-Soo Yoon, Youngil Koh
Peripheral T-cell lymphomas (PTCLs) have an aggressive biological course and poor clinical outcomes. Despite producing somewhat less-than-satisfactory results, the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remains the de facto standard in PTCL treatment. Addition of etoposide to CHOP backbone to overcome such unsatisfactory results has yielded contradictory information. We aimed to thoroughly analyze the impact of incorporating etoposide into first-line treatment. Using merged data from the Korean National Health Insurance Service and National Cancer Registry, a total of 1933 patients (median age, 58 years) were evaluated for clinical characteristics and treatment outcomes...
November 14, 2017: Blood Advances
https://www.readbyqxmd.com/read/29259783/recent-advances-in-understanding-and-managing-t-cell-lymphoma
#15
REVIEW
Jun Ho Yi, Seok Jin Kim, Won Seog Kim
Owing to the rarity of peripheral T-cell lymphoma (PTCL) and the heterogeneity of subtypes, there are no compelling data to guide the therapeutic approaches for such patients. Over the years, there have been remarkable advances in molecular subtyping and treatment of PTCL, although there are still many areas to be explored. In this review, we summarize recent updates on the evolution of understanding and treatment for PTCL.
2017: F1000Research
https://www.readbyqxmd.com/read/29245981/co-targeting-aurora-kinase-with-pd-l1-and-pi3k-abrogates-immune-checkpoint-mediated-proliferation-in-peripheral-t-cell-lymphoma-a-novel-therapeutic-strategy
#16
Shariful Islam, Eric Vick, Bryan Huber, Carla Morales, Catherine Spier, Laurence Cooke, Eric Weterings, Daruka Mahadevan
Peripheral T-cell non-Hodgkin lymphoma (PTCL) are heterogeneous, rare, and aggressive diseases mostly incurable with current cell cycle therapies. Aurora kinases (AKs) are key regulators of mitosis that drive PTCL proliferation. Alisertib (AK inhibitor) has a response rate ∼30% in relapsed and refractory PTCL (SWOG1108). Since PTCL are derived from CD4+/CD8+ cells, we hypothesized that Program Death Ligand-1 (PD-L1) expression is essential for uncontrolled proliferation. Combination of alisertib with PI3Kα (MLN1117) or pan-PI3K inhibition (PF-04691502) or vincristine (VCR) was highly synergistic in PTCL cells...
November 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/29242879/translesion-dna-synthesis-across-double-base-lesions-derived-from-cross-links-of-an-antitumor-trinuclear-platinum-compound-primer-extension-conformational-and-thermodynamic-studies
#17
O Novakova, N P Farrell, V Brabec
Polynuclear platinum complexes represent a unique structural class of DNA-binding agents of biological significance. They contain at least two platinum coordinating units bridged by a linker, which means that the formation of double-base lesions (cross-links) in DNA is possible. Here, we show that the lead compound, bifunctional [{trans-PtCl(NH3)2}2μ-trans-Pt(NH3)2{H2N(CH2)6NH2}2]4+ (Triplatin or BBR3464), forms in DNA specific double-base lesions which affect the biophysical and biochemical properties of DNA in a way fundamentally different compared to the analogous double-base lesions formed by two adducts of monofunctional chlorodiethylenetriamineplatinum(ii) chloride (dienPt)...
December 15, 2017: Metallomics: Integrated Biometal Science
https://www.readbyqxmd.com/read/29233821/activity-of-the-pi3k-%C3%AE-%C3%AE-inhibitor-duvelisib-in-a-phase-i-trial-and-preclinical-models-of-t-cell-lymphoma
#18
Steven M Horwitz, Raphael Koch, Pierluigi Porcu, Yasuhiro Oki, Alison Moskowitz, Megan Perez, Patricia Myskowski, Adam Officer, Jacob D Jaffe, Sara N Morrow, Kerstin Allen, Mark Douglas, Howard Stern, Jennifer Sweeney, Patrick Kelly, Virginia Kelly, Jon C Aster, David Weaver, Francine M Foss, David M Weinstock
Duvelisib (IPI-145) is an oral inhibitor of phosphoinositide-3-kinase (PI3K)-δ/γ isoforms currently in clinical development. PI3K-δ/γ inhibition may directly inhibit malignant T-cell growth, making Duvelisib a promising candidate for patients with peripheral (PTCL) or cutaneous (CTCL) T-cell lymphoma. Inhibition of either isoform may also contribute to clinical responses by modulating nonmalignant immune cells. We investigated these dual effects in a TCL cohort from a Phase 1, open-label study of Duvelisib in patients with relapsed or refractory PTCL [n=16] and CTCL [n=19], along with in vitro and in vivo models of TCL...
December 12, 2017: Blood
https://www.readbyqxmd.com/read/29217426/composite-lymphoma-of-follicular-b-cell-and-peripheral-t-cell-types-with-distinct-zone-distribution-in-a-75-year-old-male-patient-a-case-study
#19
John Tanaka, Pu Su, Catherine Luedke, Rachel Jug, Lian-He Yang, Kristen Deak, Sarah Horn, Yang Zhang, Marc Delos Angeles, Yi Xie, Endi Wang
Composite lymphoma (CL) of T-/B-cell type is rare, and follicular lymphoma composite with peripheral T-cell lymphoma (PTCL) has not previously been reported. We report such a case with both neoplastic components displaying a unique zone of distribution. A 75-year-old male patient presented with generalized lymphadenopathy. Sections of axillary lymph node demonstrated potentially two clonal processes, PTCL with aberrant CD20 expression and follicular lymphoma. Interestingly, the two neoplastic components were confined to their respective classic distribution zones, with PTCL occupying the interfollicular areas and follicular lymphoma residing in follicles...
December 4, 2017: Human Pathology
https://www.readbyqxmd.com/read/29212973/-refractory-cd20-positive-peripheral-t-cell-lymphoma-showing-loss-of-cd20-expression-after-rituximab-therapy-and-gain-of-cd20-expression-after-administration-of-vorinostat-and-gemcitabine
#20
Kazuaki Teshima, Hideaki Ohyagi, Masaaki Kume, Satsuki Takahashi, Masahiro Saito, Naoto Takahashi
A 79-year-old male patient presented with systemic lymphadenopathy. A lymph node biopsy revealed effacement of the normal nodal architecture with diffuse proliferation of medium-sized atypical lymphoid cells. Southern blot analyses demonstrated rearrangement of the T-cell receptor gene but not the immunoglobulin heavy chain gene. He was diagnosed with CD20-positive peripheral T-cell lymphoma (PTCL), NOS. Although he achieved partial remission after six cycles of R-CHOP, he relapse occurred after 2 months. CD20-negative conversion was confirmed in the lymph node, which was positive for CCR4, and the skin at the time of relapse...
2017: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
keyword
keyword
47694
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"